Meds, Mind, Body & Benefits > Research News & Studies

BIT 225

<< < (2/2)

I don't see anything significant in it, but that isn't a shock as it depends on what it does to Vpu. I had a think today about the macrophage thing. There are many NNRTIs that reach macrophages, its nukes that have the biggest problem I understand (because of the way they are taken up). I guess the key for this drug is like that of any other - does it reach macrophages in the correct places where current drugs can not reach? That's a pharmacokinetics question that we don't have the answer to. My question to them is do they have information that it goes to places not touched or are they saying that because it can reach macrophages it has the potential to do better than current therapy? I'd be more excited if it were the former, as the latter would sound like salesmanship.

I await their phase II study results in a year..



[0] Message Index

[*] Previous page

Go to full version